LIGAND-TARGETED LIPOSOMES DIRECTED AGAINST PATHOLOGICAL VASCULATURE
- 1 January 2002
- journal article
- Published by Taylor & Francis in Journal of Liposome Research
- Vol. 12 (1-2) , 129-135
- https://doi.org/10.1081/lpr-120004785
Abstract
The development of liposomes targeted to angiogenic endothelial cells offers exciting prospects for intervention in cancer and inflammation. Several proteins are (strongly) over-expressed on angiogenic endothelial cells as compared to the quiescent endothelium, and could potentially serve as targets for site-specific drug delivery. In this contribution particular attention is given to the design of targeted long-circulating liposomes directed against the alpha v beta 3-integrin protein.Keywords
This publication has 12 references indexed in Scilit:
- Angiogenesis in cancer and other diseasesNature, 2000
- Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapyInternational Journal of Cancer, 2000
- Anti-angiogenic agentsEuropean Journal Of Cancer, 2000
- Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactionsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2000
- Mechanisms of angiogenesis and arteriogenesisNature Medicine, 2000
- New paradigms for the treatment of cancer: The role of anti-angiogenesis agentsPublished by Elsevier ,2000
- Tumor Vasculature Targeted Therapies: Getting the Players OrganizedBiochemical Pharmacology, 1998
- The αvβ3 integrin “vitronectin receptor”The International Journal of Biochemistry & Cell Biology, 1997
- Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed IntegrinsNature Biotechnology, 1995
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995